<DOC>
	<DOCNO>NCT02342379</DOCNO>
	<brief_summary>Dual center , single arm , two-stage , non-blinded , prospective study combination therapy bevacizumab 10mg/kg TH-302 670mg/m2 every 2 week ( 6 week cycle ) disease progression .</brief_summary>
	<brief_title>TH-302 Combination With Bevacizumab Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>At least 18 year age Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee Histologically confirm glioblastoma Progression follow standard combine modality treatment radiation temozolomide chemotherapy , well bevacizumab Recovered toxicity prior therapy grade 0 1 ECOG performance status ≤ 2 Life expectancy least 3 month Acceptable liver function : 1 . Bilirubin ≤ 1.5 time upper limit normal 2 . AST ( SGOT ) ALT ( SGPT ) ≤ 3.0 time upper limit normal ( ULN ) ; Acceptable renal function : a. Serum creatinine ≤ULN Acceptable hematologic status ( without hematologic support ) : 1 . ANC ≥1500 cells/uL 2 . Platelet count ≥100,000/uL 3 . Hemoglobin ≥9.0 g/dL All woman childbearing potential must negative serum pregnancy test male female subject must agree use effective mean contraception ( surgical sterilization use barrier contraception either condom diaphragm conjunction spermicidal gel IUD ) partner entry study 6 month last dose The subject receive warfarin ( coumarin derivative ) unable switch low molecular weight heparin ( LMWH ) first dose study drug . The subject evidence acute intracranial intratumoral hemorrhage either MRI computerize tomography ( CT ) scan . Subjects resolve hemorrhage , punctate hemorrhage , hemosiderin eligible . The subject unable undergo MRI scan ( eg , pacemaker ) . The subject receive enzymeinducing antiepileptic agent within 14 day study drug ( eg , carbamazepine , phenytoin , phenobarbital , primidone ) . The subject recover National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) v4.03 Grade ≤ 1 AEs ( except alopecia , anemia lymphopenia ) due surgery , antineoplastic agent , investigational drug , medication administer prior study drug . The subject evidence wound dehiscence Severe chronic obstructive pulmonary disease hypoxemia ( require supplementary oxygen , symptom due hypoxemia oxygen saturation &lt; 90 % pulse oximetry 2 minute walk ) opinion investigator physiological state likely cause normal tissue hypoxia The subject pregnant breastfeeding . The subject serious intercurrent illness , : 1. hypertension ( two blood pressure [ BP ] reading perform screen &gt; 150 mmHg systolic &gt; 100 mmHg diastolic ) despite optimal treatment 2. nonhealing wound , ulcer , bone fracture 3. significant cardiac arrhythmia 4. untreated hypothyroidism 5. uncontrolled active infection 6. symptomatic congestive heart failure unstable angina pectoris within 3 month prior study drug 7. myocardial infarction , stroke , transient ischemic attack within 6 month 8. gastrointestinal perforation , abdominal fistula , intra abdominal abscess within 1 year 9. history clinical evidence pancreatitis within 2 year The subject inherit bleed diathesis coagulopathy risk bleeding . The subject receive follow prior anticancer therapy : 1 . Nonstandard radiation therapy brachytherapy , systemic radioisotope therapy , intraoperative radiotherapy ( IORT ) . Note : stereotactic radiosurgery ( SRS ) allow 2 . Nonbevacizumab systemic therapy ( include investigational agent smallmolecule kinase inhibitor ) noncytotoxic hormonal therapy ( eg , tamoxifen ) within 7 day 5 halflives , whichever short , prior first dose study drug 3 . Biologic agent ( antibody , immune modulators , vaccine , cytokine ) within 21 day prior first dose study drug 4 . Nitrosoureas mitomycin C within 42 day , metronomic/protracted lowdose chemotherapy within 14 day , cytotoxic chemotherapy within 28 day , prior first dose study drug 5 . Prior treatment carmustine wafer 6 . Prior treatment TH302</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>